📣 EYE CARE NEWS ROUND UP 👁
🔥 NEW FDA APPROVALS
Iveric Bio, An Astellas company receives U.S FDA approval of a new treatment for Geographic Atrophy. IZERVAY is the only approved GA treatment with a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. Pravin Dugel, MD, President, Iveric Bio, An Astellas Pharma Company: “We would like to thank everyone involved in reaching this milestone and helping us deliver on our commitment to pioneer transformational therapies for retinal disease.”
FDA approves treatment for Blepharitis: Xdemvy, manufactured by Tarsus Pharmaceuticals, Inc. Pharmaceuticals, is the first treatment approved by the US Food and Drug Administration that directly targets demodex mites. Bobak Azamian, MD, PhD, (CEO): "We are thrilled to announce the FDA approval of Xdemvy for the treatment of demodex blepharitis and look forward to making this product broadly available".
👀 THEA ACQUIRES PROQR THERAPEUTICS
Laboratoires Théa & ProQR Therapeutics have announced an agreement in which ProQR will divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Daniel de Boer founder and Chief executive Officer of ProQR: “We seek to develop a new class of therapies for patients with high unmet need”.
🎒 JOHNSON & JOHNSON VISION LAUNCHES MYOPIC BACK-TO-SCHOOL CAMPAIGN
Johnson & Johnson Vision have announced that its ACUVUE Ability Brand is initiating a Back-to-School campaign to inform parents about the growing risk of myopia and encourage them to schedule a comprehensive eye exam for their children ahead of the new school year.
👂 ESSILORLUXOTTICA TO INTRODUCE HEARING CARE FRAMES
EssilorLuxottica has announced plans to expand its operations into the hearing care market. Launching in the second half of 2024, they will be debuting with a product that embeds a high-quality hearing technology invisibly into fashion eyewear. Francesco Milleri, Chairman and CEO: “We are uniquely positioned to open up a new avenue for the industry by addressing the need for good hearing with innovative technologies”.